Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2017)
18 slides from Cocrystal Pharma's investor presentation, Jan 9, 2017
Slide 1: Cocrystal Pharma Antiviral Therapies
C@CRYSTAL Antiviral Therapies PHARMA. 1
Slide 2: Forward Looking Statements
Forward Looking Statements + This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include, but are not limited to, delays in manufacturing created by third parties and the ability of clinical research organizations to recruit patients. F
Slide 3: Opportunities
Opportunities Significant unmet medical needs across a variety of viral infections Seasonal and Leading causes of * Chronic (potentially pandemic liver failure and orphan indication) liver cancer + Acute gastroenteritis Estimated economic Opportunity for shorter No treatment available impact of seas
Slide 4: Company Highlights
Company Highlights ® Clinical stage antiviral company = Multiple opportunities in different viral diseases Influenza PB-2 inhibitors, PA inhibitors, PB-1 inhibitors Hepatitis C Non-nucleoside inhibitors, nucleoside inhibitors, helicase inhibitors, NSSA inhibitors Norovirus Nucleoside inhibitors, non
Slide 5: Next Wave CC-31244 Combination Therapy with Existing HCV DAAs
Next Wave CC-31244 Combination Therapy with Existing HCV DAAs Potential best-in-class HCV NNI with a strong profile > Pan-genotypic, potent NSSB polymerase inhibitor > Developed by Cocrystal’s proprietary structure-based discovery platform > High barrier to drug resistance > Effective against known
Slide 6: HCV DAA Combinations
HCV DAA Combinations Multiple opportunities in developing combination ultra-short, all oral pan-genotypic cure with partners Pan-genotypic NSSB NNI Pan-genotypic NSSA Inhibitor Oral, Pan-genotypic, Pan-genotypic =) Ultra-short therapy NSSB Nuc Pan-genotypic Ns3 PI
Slide 7: CC-31244 Phase 1a Clinical Trial Update
CC-31244 Phase la Clinical Trial Update = Asingle- and multiple-dose assessment of the safety and pharmacokinetics of pan-genotypic NNI, CC-31244 > Single-dose completed: five cohorts of healthy volunteers at 10, 50, 100, 200, and 400 mg > Multiple-dose completed: two cohorts of healthy volunteers a
Slide 8: CC-31244 Phase 1b Clinical Trial Update
CC-31244 Phase lb Clinical Trial Update = Proof-of-concept Phase 1b study near completion > HCV infected subjects with minimal fibrosis and no significant co-morbidities > Repeat-dose, randomized, monotherapy trial (400 mg QD x 7 days) > Substantial and durable antiviral effect with an average 3 log
Slide 9: Pan-genotypic NNI, CC-31244: Demonstration of Enabling Technology
Pan-genotypic NNI, CC-31244: Demonstration of Cocrystal’s Enabling Technology HCV GT1 — GT6 NSSB polymerase crystals BE bia __ HEV NSSB polymerase: Proven track record for high quality antiviral leads C@CRYSTAL
Slide 10: Crystallography Technology Platform
Crystallography Technology Platform Initial HCV hit * Ability to quickly grow ultra-high resolution crystals of replication enzymes * Rapid turnaround of structural information through highly automated X -ray data processing and refinement " Discovery of novel binding sites - overlay structure of fr
Slide 11: Structure-Based Drug Discovery Process
Structure-Based Drug Discovery Process: Investing on Attractive Drug Binding Pockets a Near atomic resolution, X-ray quality crystal production Drug pocket selection Hit-to-lead process Lead optimization Drug candidates
Slide 12: Great Opportunity in Influenza Antiviral Market
Great Opportunity in Influenza Antiviral Market = Seasonal and pandemic infection = 3-5 million cases of severe illness per year = 250,000 — 500,000 deaths worldwide* = Total estimated economic impact of seasonal flu in US: $87 billion* = Approved influenza therapy has limitation “Reference: hitos:/
Slide 13: Influenza: Still Significant Unmet Need
Influenza: Still Significant Unmet Need = Approved influenza antivirals administered early, within 48 hours of onset of Flu symptoms Antiviral Developer MOA/Dosing Oseltamivir Gilead/ Oral neuraminidase (Tamiflu) Genentech Inhibitor/75 mg bid for five days Zanamivir Biota/ Inhaled neuraminidase inhi
Slide 14: Desirable Properties For Influenza Antivirals
Desirable Properties For Influenza Antivirals = Superior pharmacological properties > Broad spectrum against pandemic and seasonal influenza strains > Efficacious against neuraminidase inhibitor (Tamiflu) resistant strains > Novel mechanism of action = Flexible drug administration routes. i.e., oral
Slide 15: Polymerase Complex Is Essential For Influenza Viral Replication
Polymerase Complex Is Essential For Influenza Viral Replication
Slide 16: Influenza A Preclinical PB-2 Lead Selected
Influenza A Preclinical PB-2 Lead Selected Influenza PB2 crystals = CC-42344 selected as preclinical lead ~ d = Favorable PK profiles = Excellent anti-influenza activity against pandemic, seasonal, and Tamiflu resistant influenza strains = Binds a highly conserved PB2 site = Novel mechanism of actio
Slide 17: Early Stage Programs
Early Stage Programs = CRISPR-Cas9 program > In-licensed from Duke University and Emory University for treatment of HBV and HPV > POC animal model studies will be initiated = Norovirus program > Structure-based NNI discovery ongoing > Noro and Norwalk polymerase crystals developed > Noro nucleoside
Slide 18: Summary
Summary HCV NNI CC-31244: Complete the ongoing Phase 1b study, and initiate Phase 2a Influenza PB-2 CC-42344: Lead candidate selected and moving to initiate IND-enabling studies Open to partner(s) for HCV assets in strategic locations Continue Noro, and CRISPR-Cas9 (HepB and HPV) programs
Cocrystal Pharma — Investor Presentation (January 2017) on 6ix